Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches 
    		ESMO 2018 Congress
    	
    	
    	
    
        Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as targeted therapy for biliary cancer.
    
    
    
    
       
       
    		
		
		
        
		
		
		
		Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new standard of care in renal cell carcinoma (Abstract LBA6_PR).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Sibylle Lobil, MD, PhD, of the German Breast Group, discusses findings in metastatic breast cancer from the IMpassion130 trial in triple-negative disease and from the PALOMA3 and SOLAR-1 trials in hormone receptor–positive, HER2-negative disease (Abstracts LBA1_PR, LBA2_PR, LBA3_PR).
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or were intolerant of, prior hedgehog pathway inhibitor therapy.
For more information about this ongoing trial, visit clinicaltrials.gov
ClinicalTrials.gov ID: NCT03132636
			
			
     	
    
       
       
    		
		
		
        
		
		
		
		Jeffrey S. Weber, MD, PhD, of the NYU Langone Perlmutter Cancer Center, discusses how long people with melanoma should be treated with PD-1 blockade and the data on remission rates.